FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 804 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... June 20, 2025 Should People Over Age 75 Be Screened for Colorectal Cancer? June 15, 2021 FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... February 21, 2025 Load more HOT NEWS Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... Why do non-smokers face delays in getting a lung cancer diagnosis? Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to...
